Insider Selling: Personalis (NASDAQ:PSNL) CEO Sells $1,315,000.00 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 100,000 shares of Personalis stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.15, for a total value of $1,315,000.00. Following the sale, the chief executive officer owned 235,986 shares in the company, valued at $3,103,215.90. The trade was a 29.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Trading Up 3.4%

Shares of NASDAQ:PSNL traded up $0.43 during midday trading on Friday, reaching $13.02. The company had a trading volume of 8,354,545 shares, compared to its average volume of 3,223,766. The stock has a market cap of $1.36 billion, a P/E ratio of -12.76 and a beta of 2.28. The company’s 50 day moving average price is $8.42 and its 200 day moving average price is $8.29. Personalis, Inc. has a 52-week low of $3.84 and a 52-week high of $13.37.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. Research analysts forecast that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd boosted its stake in Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the period. Deutsche Bank AG increased its position in shares of Personalis by 4.5% during the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after buying an additional 1,655 shares during the period. Royal Bank of Canada increased its position in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the period. Howland Capital Management LLC lifted its holdings in shares of Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after buying an additional 2,500 shares in the last quarter. Finally, Intech Investment Management LLC boosted its position in shares of Personalis by 23.4% in the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after acquiring an additional 3,851 shares during the period. 61.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PSNL has been the topic of several research analyst reports. Morgan Stanley dropped their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. BTIG Research dropped their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Finally, Needham & Company LLC increased their price target on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.